Attention deficit/hyperactivity disorder, commonly known as ADHD, is the diagnostic name given to a persistent developmental condition, characterised by a set of behavioural symptoms falling broadly into problems with inattention, hyperactivity and impulsivity. To meet diagnosis, these symptoms should occur across a number of settings, and result in impairment to day-to-day living.

It is said that roughly 2-5% of young people are affected by ADHD, though the precise numbers are unclear. It is more frequently diagnosed in boys.

Although traditionally associated with children, ADHD can be diagnosed at any age, and recent research has highlighted the impact of ADHD in adults. Diagnosis, however, is most commonly made in children aged six and upwards.

Alongside symptoms of ADHD, people often report difficulties relating to low mood, anxiety and disturbed sleep.

Like many developmental and mental health conditions, the symptoms exist on a continuum. Periods of restlessness and inattentiveness are perfectly normal and do not necessarily indicate ADHD.

What we know already

Through longitudinal studies, we know that often the symptoms of ADHD can improve with age; however, many adults continue to experience difficulties.

Similarly, we know that ADHD is more common in people with learning disabilities.

Through advances in neuroimaging and neuropsychological assessment, we have been able to gain a better understanding of the way ADHD affects cognition (e.g. working memory and other executive function),emotion regulation and behaviour. Similarly, we have gained a better understanding of neurochemical factors, such as the role of dopamine uptake.

Evidence suggests that multimodal treatments (i.e. combination of medication and behavioural therapy) can be highly effective in the management of ADHD.

Areas of uncertainty

The causes of ADHD remain largely unclear, although there appears to be a clear hereditary component. Similarly, other factors such as low birth weight, premature birth, brain injury, toxic exposure at an early age, and environmental factors have all been suggested.

Due to the historical lack of research into disadvantaged groups, we know less about ADHD in ethnic minorities; however, this is improving. Similarly, only relatively recently have gender differences been convincingly explored.

There had been considerable research, of varying quality, into alternative treatments of ADHD. Long-chain polyunsaturated fatty acids, for example, have been shown to demonstrate small positive effects, however this area of research remains methodologically weak.

What’s in the pipeline?

As neuroimaging techniques improve, there will no doubt be a greater understanding of which aspects of brain functioning are associated with symptoms of ADHD.

Similarly, genetic (and other causal) factors continue to be explored, improving our understanding.

Such increases in understanding of the causes and mechanisms involved in ADHD are likely to lead to improved, targeted, interventions. Whilst multimodal treatments have been shown to be largely effective, the benefit often dissipates over time. Similarly, whilst some people continue to improve following treatment, others do not. Developing these treatments will likely remain a priority.


Gillies, D., Sinn, J. K., Lad, S. S., Leach, M. J. and Ross, M. J. (2012). Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews. [Abstract]

Murray, D. W., Arnold, L. E., Swanson, J., Wells, K., Burns, K., Jensen, P., … & Strauss, T. (2008). A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA). Current psychiatry reports, 10, 424-431. [Abstract]


Written by: Patrick Kennedy-Williams
Reviewed by: Joff Jones, Anna Adlam
Last updated: Sep 2015
Review due: Sep 2016

Our ADHD Blogs

Drug treatment of ADHD in children and young people with ASD #CAMHScampfire

Mental Health Awareness concept for ADHD. letters spelling ADHD.

Douglas Badenoch appraises an up-to-date systematic review and decision pathway for the drug treatment of ADHD symptoms in young people with autism spectrum disorder.

Follow #CAMHScampfire on Twitter at 5pm BST on Tuesday 25th May for an online journal club discussing this paper. Or sign up now to join the free webinar hosted by ACAMH.

[read the full story...]

Majority of people with ADHD in Ireland still thought to be untreated, despite increase in treatment rates


In her debut blog, Poppy Ellis Logan summarises a longitudinal study which finds rates of ADHD prescription increased in Ireland between 2005 and 2015.

[read the full story...]

Is there a causal link between mental health problems and risk of COVID-19 infection?


In his debut blog, Andrew Steptoe summarises two recent papers using electronic health record datasets, which suggest that having a psychiatric diagnosis may put people at risk of COVID-19 infection.

[read the full story...]

Sleep problems in infancy: a possible risk factor for ADHD?


Jack Barton summarises a recent longitudinal study from Finland, which suggests that sleep difficulties in infancy are associated with symptoms of inattention and hyperactivity at the age of 5 years.

[read the full story...]

ADHD remission: why do some children ‘outgrow’ ADHD whilst others don’t?


A group of UCL Mental Health Masters students summarise a recent literature review that explores the potential pathways to ADHD remission.

[read the full story...]

Psychosis during ADHD treatment with methylphenidate or amphetamines


Samuele Cortese reports on a recent study of 13-25 year old people with ADHD, which looks at the comparative risk of psychosis during treatment with methylphenidate and amphetamines.

[read the full story...]

Who gets bullied? Using genetic information to identify individual vulnerabilities


Lucy Bowes explores a multi-polygenic score approach to identifying individual vulnerabilities associated with the risk of bullying, which suggests that depression, ADHD, risk taking, BMI and intelligence are independently associated with exposure to bullying.

[read the full story...]

Alternatives to medication for children and young people with ADHD


Joff Jones summarises a recent systematic review, which looks at the evidence for a wide range of non-pharmacological treatments for ADHD. The review finds the strongest evidence for diet, child/parent training and behavioural interventions.

[read the full story...]

Medication for ADHD: what works for adults, adolescents and children


Dean Connolly is impressed by a recent systematic review and network meta-analysis, which compares the efficacy and tolerability of medication for ADHD in children, young people and adults.

[read the full story...]

The cost of persuasive design: digital media use and ADHD


Elvira Perez Vallejos and David Daley consider the findings of a recent cohort study in JAMA that looks into the association between digital media use and subsequent symptoms of ADHD in adolescents.

[read the full story...]